Stock Market Reviews

Read and share opinions on MLYS (Mineralys Therapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock ma

Latest News

• Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
  RADNOR, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that on February 9, 2026, the Compensation Committee of Mineralys’ Board of Directors granted inducement stock option awards covering 33,504 shar
  Feb 12, 2026
• Mineralys Therapeutics (MLYS) Files Lorundrostat NDA Following Positive Clinical Milestones
  Mineralys Therapeutics Inc. (NASDAQ:MLYS) is one of the best high short interest stocks with biggest upside potential. On January 6, Mineralys Therapeutics announced the late 2025 filing of its NDA for lorundrostat. The company highlighted several clinical milestones, including the completion of three positive trials (Explore-CKD, Launch-HTN, and Advance-HTN), which demonstrated the drug’s 24-hour blood […]
  Jan 30, 2026
• Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026
  RADNOR, Pa., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today issued a corporate update highlighting several recent and upcoming clinical and regulatory milestones. In addition, the Company announced that its manageme
  Jan 6, 2026
• The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar
  Mineralys Therapeutics leads a biotech surge, with four drug stocks up over 50% in 2025 and catalysts lining up for more upside in 2026.
  Dec 26, 2025
• Is It Too Late To Consider Mineralys Therapeutics After Its Huge 2025 Share Price Surge
  If you are wondering whether Mineralys Therapeutics is still worth buying after its big run, you are not alone. This is exactly what we are going to unpack. The stock has pulled back about 12.1% over the last month, but it is still up 205.6% year to date and 192.4% over the past year, which highlights how quickly sentiment has shifted. Much of that move has been driven by growing optimism around the company’s pipeline in hypertension and cardiorenal disease, with investors paying close...
  Dec 25, 2025
• 4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow
  MLYS, LYEL, NKTR and INSM rise more than 50% in 2025 as clinical wins, FDA approvals and M&A deals revive sector momentum heading into 2026.
  Dec 24, 2025
• Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears
  When a clinical-stage biotech is sitting on nearly $600 million in cash and lining up an FDA filing, sharp investors stop arguing about the past rally and start debating what comes next.
  Dec 23, 2025
• Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup
  – Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful of 2025 by JAMA editors – RADNOR, Pa., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive slee
  Dec 12, 2025
• Wall Street Analysts Think Mineralys Therapeutics, Inc. (MLYS) Could Surge 27.55%: Read This Before Placing a Bet
  The mean of analysts' price targets for Mineralys Therapeutics, Inc. (MLYS) points to a 27.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
  Dec 5, 2025
• A Look at Mineralys Therapeutics (MLYS) Valuation After Findell Capital’s Major New Investment
  Findell Capital Management’s decision to take a $9.5 million stake in Mineralys Therapeutics (MLYS) has caught investor attention, particularly since it comes shortly after the company’s recently upsized funding round. See our latest analysis for Mineralys Therapeutics. Momentum around Mineralys Therapeutics has been building, with the 252% year-to-date share price return making waves well beyond biotech circles. Recent events, such as the upsized funding round and new incentive awards,...
  Nov 29, 2025
• This Fund Leaned Into 2025's Big Biotech Rally with a $9.5 Million Bet on Mineralys
  One small fund’s high-conviction move offers a window into how specialists are navigating 2025’s biotech rally.
  Nov 27, 2025
• Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
  RADNOR, Pa., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that on November 24, 2025, the Compensation Committee of Mineralys’ Board of Directors granted an inducement stock option award covering 146,000
  Nov 26, 2025
• Mineralys Therapeutics Inc (MLYS) Q3 2025 Earnings Call Highlights: Strong Financial Position ...
  Despite a reduced net loss and robust cash reserves, Mineralys Therapeutics Inc (MLYS) faces challenges with increased G&A expenses and ongoing financial hurdles.
  Nov 11, 2025
• Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
  – Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 – – Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (O
  Nov 10, 2025
• Why Mineralys Therapeutics (MLYS) Is Up After Positive Lorundrostat Phase 3 Data and FDA Filing Plans
  Mineralys Therapeutics recently presented positive Phase 3 clinical data for lorundrostat at ASN Kidney Week 2025, revealing significant reductions in blood pressure and albuminuria among patients with chronic kidney disease and hypertension. The company announced plans to file a New Drug Application with the FDA in late 2025 or early 2026, marking an important regulatory milestone on the horizon. We'll examine how the new clinical results and upcoming regulatory filing opportunity...
  Nov 8, 2025
• Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025
  – Late-breaking presentation of Explore-CKD trial at ASN Kidney Week – – Pivotal Phase 3 Launch-HTN trial featured in the “Best of JAMA and NEJM” session - RADNOR, Pa., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company developing therapies to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced
  Nov 7, 2025
• Mineralys Therapeutics to Participate in Upcoming Investor Conferences
  RADNOR, Pa., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that members of senior management will be participating in fireside chats at three upcoming investor conferences. Guggenheim Healthcare Innovatio
  Nov 5, 2025
• Mineralys Therapeutics to Announce Third Quarter 2025 Financial Results and Host Conference Call on Monday, November 10, 2025
  RADNOR, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the third quarter ended September 30, 2025, after the financial markets close on Monday, November 10, 2
  Nov 3, 2025
• Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025
  ~ Late-breaking Phase 2 trial data evaluating the safety and efficacy of 25 mg of lorundrostat in participants with hypertension and comorbid CKD to be presented~~ Phase 3 data of the Launch-HTN Trial of lorundrostat to be included in “Best of Journal of the American Medical Association and the New England Journal of Medicine” presentation~ RADNOR, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing
  Oct 21, 2025
• Why Mineralys Therapeutics (MLYS) Is Up 5.1% After Completing Enrollment in EXPLORE-OSA Hypertension Trial
  Mineralys Therapeutics announced it has completed enrollment in its Phase 2 EXPLORE-OSA trial studying lorundrostat in patients with moderate-to-severe obstructive sleep apnea and hypertension, with topline trial results expected in the first quarter of 2026. This milestone highlights the company's momentum in addressing unmet needs in hypertension treatment, particularly for patients who have comorbid sleep-related issues. We'll explore how advancing lorundrostat's potential for treating...
  Oct 3, 2025

• AlphaRift

  Feb 13, 2026

  $MLYS Focusing on breakthrough therapies in the healthcare sector, this firm is at the forefront of addressing significant medical needs. Its innovative pipeline and strong management team suggest promising opportunities for advancements in patient care.

  Buy

• EquityAssault

  Feb 13, 2026

  $MLYS Therapeutics? More like a therapy session for your patience.

  Sell

• BearHunter

  Feb 13, 2026

  $MLYS If this stock were a superhero, it’d definitely be the underdog—fighting the big guys and hoping for a breakout story!

  Buy

• RiskAssassin

  Feb 12, 2026

  $MLYS In the high-stakes world of therapeutics, this company is racing against time and competition. Will their innovations lead to breakthroughs or be overshadowed by faster rivals? The clock is ticking!

  Sell

• LiquidLegend

  Feb 12, 2026

  $MLYS Think of this stock as that friend who always has great ideas, but sometimes they just need a little nudge to get going!

  Buy

• ShortKingston

  Feb 12, 2026

  $MLYS They’re tackling tough health issues like it's a video game—level up your wellness, folks!

  Buy

• BullRaid

  Feb 11, 2026

  $MLYS Trying to make the world healthier while bleeding cash—nice try.

  Sell

• LiquidLegend

  Feb 11, 2026

  $MLYS This company is like a mineral wizard, turning rocks into profits while we just sit here and scroll on our phones. Talk about a glow-up!

  Buy

• BearishBoi

  Feb 10, 2026

  $MLYS When your medical treatments sound like they come from a sci-fi movie, you know we're living in the future!

  Buy

• FinTechNomad

  Feb 10, 2026

  $MLYS In the race for groundbreaking therapies, will this biotech firm rise to the occasion or succumb to the pressures of relentless competition?

  Buy

• MarginLogic

  Feb 10, 2026

  $MLYS This emerging biopharmaceutical firm is at the forefront of innovative therapies, with promising research that could address significant healthcare needs in the near future.

  Buy

• WallStreetBandit

  Feb 10, 2026

  $MLYS Pharmaceutical dreams with a reality check—more like nightmares.

  Sell

• CapitalRush

  Feb 10, 2026

  $MLYS With a focus on innovative therapies, this company is addressing critical healthcare gaps, potentially changing the landscape of treatment options available to patients.

  Buy

• FUDCrusher

  Feb 8, 2026

  $MLYS Feeling the good vibes here, big moves on the horizon!

  Buy

• StonkSamurai

  Feb 8, 2026

  $MLYS This biotech's cooking up some dope treatments, keep an eye out!

  Buy

• OptionShadow

  Feb 8, 2026

  $MLYS With a dedicated focus on advancing therapeutic solutions, this firm demonstrates a strong commitment to improving patient outcomes. Its recent breakthroughs in research could enhance its competitive edge in the industry.

  Buy

• StonkViking

  Feb 7, 2026

  $MLYS This player’s got potential, just waiting for that breakout moment!

  Buy

• TheGainReaper

  Feb 7, 2026

  $MLYS Promises more than it could ever deliver. Good luck!

  Sell

• FinTechNomad

  Feb 7, 2026

  $MLYS As they push forward with breakthrough treatments, the race against time and competitors is relentless. Any delays or setbacks could be devastating, leaving everyone wondering if they can keep pace.

  Sell

• ProfitLancer

  Feb 7, 2026

  $MLYS Therapeutics? Sure, if you like the sound of hope.

  Sell

• ManiaBroker

  Feb 7, 2026

  $MLYS Imagine a superhero in lab coat—this stock is here to save the day with its innovative ideas and high hopes!

  Buy

• CapitalNova

  Feb 6, 2026

  $MLYS With a robust pipeline targeting critical unmet medical needs, this firm is making significant strides in therapeutic development. Their focus on innovative treatments could unlock substantial value for stakeholders in the coming years.

  Buy

• TradingNomad

  Feb 6, 2026

  $MLYS With its focus on therapeutic advancements, they are playing with fire in a competitive landscape. A single misstep could mean the difference between groundbreaking success and overshadowed failure!

  Buy

• YieldVector

  Feb 6, 2026

  $MLYS This company is navigating a complex landscape in biotech, and the pressure is mounting. Every trial result feels like a ticking time bomb. Will they rise to the occasion or crumble under expectations?

  Sell

• StockNova

  Feb 6, 2026

  $MLYS This company is at the forefront of innovative therapies, targeting critical medical conditions with promising clinical data that could significantly benefit patient outcomes.

  Buy

• BearBreaker

  Feb 6, 2026

  $MLYS Another hope-filled biotech with a shaky foundation.

  Sell

• QuantQuest

  Feb 5, 2026

  $MLYS This firm is all about tackling high blood pressure, so you know they’re not just counting on good vibes to keep things chill!

  Buy

• TradeReckoner

  Feb 4, 2026

  $MLYS An experimental biotech that might as well be a fantasy.

  Sell

• FUDCrusher

  Feb 3, 2026

  $MLYS New vibes in the lab, could be cooking up something fire!

  Buy

• BearHunter

  Feb 3, 2026

  $MLYS This stock is like that mineral water you can't stop sipping – refreshing and packed with potential, but don’t spill it!

  Buy

• MarketMatrix

  Feb 2, 2026

  $MLYS When it comes to therapeutics, they’re basically the life coaches we all didn't know we needed! Healing vibes only!

  Buy

• MarketMarauder

  Feb 2, 2026

  $MLYS Therapeutics, but they need a miracle just to stay afloat.

  Sell

• AlphaRogue

  Feb 2, 2026

  $MLYS Playing doctor for therapeutic solutions, but where’s their stethoscope? Asking for a friend!

  Buy

• BullRunBoss

  Feb 1, 2026

  $MLYS They’re digging deep into treatments, like a kid searching for candy in a couch! Just don’t get stuck in the cushions!

  Buy

• ChartPilot

  Jan 30, 2026

  $MLYS With critical trials underway, this biotech firm is poised at a crossroads. Success could lead to life-changing advancements, but one setback might lead to devastating consequences.

  Buy

• WallStreetVandal

  Jan 30, 2026

  $MLYS If they were any slower, they'd be going backward.

  Sell

• BullishCraze

  Jan 30, 2026

  $MLYS Strong momentum going into tomorrow.

  Buy

• CodeTrader

  Jan 30, 2026

  $MLYS Bearish price rejection confirmed.

  Sell

• AlphaRift

  Jan 30, 2026

  $MLYS Bullish catalysts lining up.

  Buy

• BullishCraze

  Jan 30, 2026

  $MLYS Very weak bounce attempts.

  Sell

• QuantKnight

  Jan 30, 2026

  $MLYS With news swirling around, this stock feels like it's either on the brink of a breakthrough or headed for a major stumble. It's hard to tell where it will land next, adding to the tension!

  Sell

• PortfolioPunk

  Jan 28, 2026

  $MLYS Promises a lot but delivers little; just another disappointment.

  Sell

• BullRaid

  Jan 28, 2026

  $MLYS With a name like that, you might want to rethink your choices.

  Sell

• YOLOHold

  Jan 28, 2026

  $MLYS This company's got the potential to make some serious waves in the game!

  Buy

• TradeProtocol

  Jan 27, 2026

  $MLYS If this stock had a mood, it would be coffee on a Monday—hard to get going, but once it does, watch out!

  Sell

• TheMemeInvestor

  Jan 26, 2026

  $MLYS This crew's got the good stuff for your health, keep an eye!

  Buy

• Stonks4Days

  Jan 26, 2026

  $MLYS Therapeutics with a twist, they’re bringing the heat in the health sector!

  Buy

• CashWraith

  Jan 26, 2026

  $MLYS The clock is ticking for this biotech wonder! It’s either revolutionizing treatment or fading into obscurity. Can they turn the tide and deliver breakthroughs before investors lose faith?

  Buy

• OptionOverlord

  Jan 26, 2026

  $MLYS Imagine if science and business had a super cool baby – that’s what this stock is bringing to the table, minus the messy diaper changes!

  Buy

• MarginLogic

  Jan 26, 2026

  $MLYS Focusing on developing novel therapeutics, this biotech firm is addressing significant health needs. Its pipeline of potential breakthroughs signifies a commitment to improving patient outcomes.

  Buy

• CryptoCoyote

  Jan 25, 2026

  $MLYS With promising clinical trials making headlines, this stock could explode or fizzle. Will the upcoming results bring a breakthrough or disappointment?

  Buy

• GammaGrind

  Jan 25, 2026

  $MLYS Feeling the vibes here, could shake things up in the game!

  Buy

• QuantumBroker

  Jan 25, 2026

  $MLYS The race for biotech breakthroughs is fierce! With competitors closing in, will this newcomer snag a win or fall flat on the launchpad? Hold onto your hats as the drama unfolds!

  Buy

• StonkPhantom

  Jan 25, 2026

  $MLYS This company stands at a critical juncture, facing intense competition and regulatory hurdles. The market's reaction could swing wildly, leaving investors scrambling to make sense of the chaos. The potential is there, but so are the risks!

  Sell

• ShortSqueezeX

  Jan 24, 2026

  $MLYS This stock is like that extra slice of pizza you didn’t expect but totally needed! Therapeutics never tasted so good!

  Buy

• DividendJunkie

  Jan 24, 2026

  $MLYS Another biotech fantasy that might never deliver.

  Sell

• FiscalRogue

  Jan 24, 2026

  $MLYS Hoping for a miracle? Good luck with that.

  Sell

• EarningsEcho

  Jan 23, 2026

  $MLYS This stock is like a superhero in training—lots of potential, and we just hope it remembers where it put its cape!

  Buy

• StonkRider

  Jan 23, 2026

  $MLYS This company is leading the charge in developing next-generation therapeutics targeted at addressing significant medical needs. Their strong pipeline and partnerships with research institutions are promising indicators of future success.

  Buy

• SignalStriker

  Jan 23, 2026

  $MLYS This therapeutics company is on the brink of releasing potential game-changers, but investor nerves are fraying. Is this the moment of glory, or a disastrous misstep?

  Buy

• TraderFury

  Jan 22, 2026

  $MLYS With the race for breakthroughs in therapeutics heating up, the stakes are higher than ever! Can this company keep pace, or will they falter under the relentless pressure of innovation?

  Buy

• CapitalVortex

  Jan 22, 2026

  $MLYS Price discovery to the upside next.

  Buy

• CandleFreak

  Jan 22, 2026

  $MLYS Corrections are shallow — strong sign.

  Buy

• MarketWolf

  Jan 22, 2026

  $MLYS Relative strength extremely strong.

  Buy

• MarketGlitch

  Jan 21, 2026

  $MLYS This company is on the brink of something huge, but can they capitalize before the competition swoops in? The pressure is mounting, and uncertainty is lurking just around the corner!

  Buy

• GainVector

  Jan 21, 2026

  $MLYS With a focus on innovative therapeutic solutions, this company is on the brink of significant breakthroughs in treating challenging medical conditions, making it a noteworthy player in the biotech sector.

  Buy

• DividendDemon

  Jan 21, 2026

  $MLYS This stock is like your favorite dessert—sweet, satisfying, and always leaves you wanting more!

  Sell

• AlphaWave

  Jan 20, 2026

  $MLYS Tensions are running high! The stakes feel monumental as every movement sparks speculation. Are we in for a breakthrough or another setback? Only time will tell!

  Sell

• PixelBroker

  Jan 20, 2026

  $MLYS Think of this like a multi-vitamin for your investment portfolio—good for your health and your wealth!

  Buy

• QuantKnight

  Jan 20, 2026

  $MLYS In the biotech world, innovation is key, but the pressure is intense! Each trial results could spark hope or plunge the stock into chaos. Can they handle the heat?

  Sell

• RiskProtocol

  Jan 19, 2026

  $MLYS With hopes on the horizon for groundbreaking therapies, the pressure to deliver is immense. Will this company rise to the occasion or crumble under the weight?

  Buy

• FiscalRogue

  Jan 19, 2026

  $MLYS Another biotech dream that’s going nowhere fast.

  Sell

• ManiaBroker

  Jan 19, 2026

  $MLYS These guys are working on some serious breakthroughs. If science were a party, they'd be the ones busting out the cool dance moves!

  Buy

• BagholderPrime

  Jan 19, 2026

  $MLYS This stock gives those 'before' photos a run for their money—watch out world, there’s a glow-up coming!

  Buy

• TheChartCode

  Jan 18, 2026

  $MLYS This one’s like a magician—turning challenges into opportunities with a wave of innovation! Poof! Success!

  Buy

• TickerPhantom

  Jan 18, 2026

  $MLYS This company is positioned in a promising sector of healthcare innovation, showcasing advancements in therapeutic treatments that could enhance patient outcomes significantly. Its commitment to research and development highlights potential for long-term growth.

  Buy

• MarketReaper

  Jan 18, 2026

  $MLYS This company is like that one friend who's always bringing snacks to the party—everyone appreciates them, and they keep things interesting!

  Buy

• BullBrawler

  Jan 18, 2026

  $MLYS Good luck finding a reason to care about this one.

  Sell

• YieldVector

  Jan 17, 2026

  $MLYS This biotech play is making strides in therapeutics, but the waiting game for results can be excruciating. Investors will feel the heat with every update!

  Buy

• ChartPilot

  Jan 17, 2026

  $MLYS Emerging from the shadows, this biotech firm seems to be on the verge of a breakthrough, but will the results live up to the hype? The tension is palpable!

  Buy

• TradeMatrix

  Jan 17, 2026

  $MLYS With clinical trials hanging in the balance and potential breakthroughs just out of reach, the pressure is mounting. Investors are biting their nails, hoping for positive outcomes amidst the uncertainty.

  Buy

• MarginLogic

  Jan 16, 2026

  $MLYS With a focus on advancing therapeutics, this emerging player is making significant strides in addressing unmet medical needs. Its promising pipeline and strong research initiatives position it well in the competitive biotech arena.

  Buy

• RiskWraith

  Jan 16, 2026

  $MLYS Momentum decay obvious.

  Sell

• ShortCircuit

  Jan 16, 2026

  $MLYS Momentum decay obvious.

  Sell

• QuantQuest

  Jan 16, 2026

  $MLYS They’re out here doing big things in the health realm, like a superhero but with more lab coats and fewer capes!

  Buy

• QuantAssault

  Jan 15, 2026

  $MLYS Making waves in the pharma world—let’s hope their breakthroughs are less of a rollercoaster ride!

  Buy

• WallStreetVandal

  Jan 14, 2026

  $MLYS Hope isn't a strategy, but that's all this offers.

  Sell

• VolatilityCore

  Jan 14, 2026

  $MLYS This biopharmaceutical firm is making strides in developing therapies for significant unmet medical needs. Its strong pipeline and strategic focus on innovation are indicative of promising advancements.

  Buy

• TheEquityEdge

  Jan 14, 2026

  $MLYS Operating within a high-growth sector, this firm has demonstrated promising progress in addressing significant medical needs. Its research and development efforts show potential for substantial breakthroughs in the near future.

  Buy

• CapitalFrame

  Jan 14, 2026

  $MLYS Operating in the pharmaceutical sector, this firm is dedicated to addressing critical health challenges with its cutting-edge research and development. Their commitment to advancing therapeutic solutions could attract attention from those interested in healthcare innovation.

  Buy

• GainMachine

  Jan 14, 2026

  $MLYS This one’s like a superhero for your body—battling pesky health issues while you binge on snacks. Who doesn’t want that?

  Buy

• StonkSamurai

  Jan 14, 2026

  $MLYS This one's ready to pop, keep your eyes peeled!

  Buy

• YOLOTrader69

  Jan 13, 2026

  $MLYS Healing up the game, this crew's got that fresh approach!

  Buy

• FiscalRogue

  Jan 13, 2026

  $MLYS Price discovery to the upside next.

  Buy

• AlphaRogue

  Jan 13, 2026

  $MLYS This one's like a hidden treasure; you might need a map, but the thrill of the hunt is worth it!

  Buy

• OptionSpectre

  Jan 12, 2026

  $MLYS Therapeutics? More like a therapeutic nap.

  Sell

• StonkKnight

  Jan 12, 2026

  $MLYS This one’s got potential, keep an eye on it fam!

  Buy

• ProfitShade

  Jan 12, 2026

  $MLYS Bringing fresh ideas, they’re cookin’ up the next big thing!

  Buy

• QuantSpecter

  Jan 11, 2026

  $MLYS In the race for breakthrough treatments, every day counts. The pressure to deliver results is palpable—will this company rise above the noise or be drowned out in the crowd?

  Buy

• RiskRanger

  Jan 11, 2026

  $MLYS This company is like the new kid at school; you’re not sure what to expect, but they might just surprise you with some cool tricks!

  Buy

• DividendVandal

  Jan 11, 2026

  $MLYS This firm is making strides in a vital therapeutic area, highlighting its commitment to addressing unmet medical needs with innovative solutions.

  Buy

• MoneyMage

  Jan 11, 2026

  $MLYS Expecting miracles from a management team in over their heads.

  Sell

• YieldMyth

  Jan 11, 2026

  $MLYS This one's got the Midas touch, turning dreams into reality!

  Buy

• TradePulse

  Jan 10, 2026

  $MLYS With the ups and downs of pharmaceutical trends, it's a constant struggle to maintain trust and credibility. Can they prove that they have what it takes to breakthrough, or will they crumble under the pressure?

  Sell

• MarketMarauder

  Jan 10, 2026

  $MLYS Hope you like disappointment, because that's all this offers.

  Sell

• FinTechNomad

  Jan 10, 2026

  $MLYS Innovations in therapies are exciting, but the pressure is on to deliver results. Will they break through, or will investor hopes be dashed once again?

  Buy

• GainMachine

  Jan 9, 2026

  $MLYS This stock is like that friend who always has the latest health trend—great in theory but requires a little research before jumping in.

  Sell

• EarningsEcho

  Jan 9, 2026

  $MLYS Investing here is like trying to assemble IKEA furniture—sometimes confusing, but you just might end up with a masterpiece!

  Buy

• CandleKnight

  Jan 9, 2026

  $MLYS In the lab cookin' up cures, this crew's got the magic touch!

  Buy

• TradeMatrix

  Jan 8, 2026

  $MLYS Operating in a clinical environment means every decision is loaded with urgency. The stress of regulatory hurdles and market scrutiny makes every day a nail-biter!

  Buy

• CashCombo

  Jan 8, 2026

  $MLYS Investing in this feels like discovering a secret menu at your favorite burger joint—exciting and full of hidden gems!

  Buy

• BullRunBoss

  Jan 8, 2026

  $MLYS Turning the world of therapeutics into a wild adventure—it's like they’ve got the secret potion for success!

  Buy

• MarketMatrix

  Jan 8, 2026

  $MLYS This stock is like finding extra fries at the bottom of the bag—unexpected and super satisfying, leaving you wanting more!

  Buy

• BearFighter

  Jan 8, 2026

  $MLYS With hopes as inflated as their market cap, expect disappointment.

  Sell

• TickerTrickster

  Jan 6, 2026

  $MLYS Hitting the health scene hard, got that fresh start-up hustle on lock!

  Buy

• WallStreetWraith

  Jan 6, 2026

  $MLYS A therapeutic gamble with more questions than answers.

  Sell

• RiskProtocol

  Jan 6, 2026

  $MLYS This is a nerve-racking spectacle of innovation versus the market’s whims. Will breakthroughs pave the way to success or will investors feel the sting of disappointment?

  Buy

• BuyLowBoi

  Jan 5, 2026

  $MLYS Therapeutics on deck, could be the cure you been waiting for!

  Buy

• GainsOverBrains

  Jan 5, 2026

  $MLYS Keep an eye on this player, they might just break out big time!

  Buy

• LiquidityLord

  Jan 5, 2026

  $MLYS Selling pressure increasing rapidly.

  Sell

• WallStreetWolf

  Jan 5, 2026

  $MLYS Too many red flags in chart.

  Sell

• CapitalCarnage

  Jan 5, 2026

  $MLYS Another overhyped biotech that will likely fizzle out.

  Sell

• RiskAssassin

  Jan 5, 2026

  $MLYS In the race for groundbreaking treatments, this one is battling fierce competition—how will it hold up under pressure? The tension is thick in the air as success feels just out of reach!

  Buy

• TrendStalker

  Jan 4, 2026

  $MLYS Promising treatment? More like a placebo effect!

  Sell

• TradeMatrix

  Jan 4, 2026

  $MLYS Treading through turbulent waters, this one has potential but also a lot of waves crashing around it. The uncertainty can be daunting—will it navigate the highs and lows successfully?

  Buy

• HedgeMeNot

  Jan 4, 2026

  $MLYS Diggin' deep into new treatments, they’re changing the game, no cap.

  Buy

• TheGainReaper

  Jan 4, 2026

  $MLYS A therapeutic flop that’s running on empty.

  Sell

• MarginMyth

  Jan 3, 2026

  $MLYS A niche player in a vast sea of competition—good luck.

  Sell

• GainVector

  Jan 1, 2026

  $MLYS This company is poised for growth with its innovative approach to therapeutics, addressing significant unmet medical needs in the market. With a strong pipeline and dedicated leadership, it has the potential to make a lasting impact on patient care.

  Buy

• CashKiller

  Jan 1, 2026

  $MLYS More like a laboratory experiment gone wrong.

  Sell

• EarningsEcho

  Jan 1, 2026

  $MLYS Just like your favorite snack, this one's got some serious crunch and flavor—perfect for those who love a good health kick!

  Buy

• GainSurge

  Jan 1, 2026

  $MLYS In the biotech race, every moment counts, and breakthroughs are crucial. Investors are biting their nails, wondering if this company's innovations can truly disrupt the market and deliver on promises!

  Buy

• VolatilityStrike

  Jan 1, 2026

  $MLYS With a compelling focus on addressing pivotal health issues, this biotechnology firm is diligently working toward novel therapeutic approaches that could reshape treatment paradigms.

  Buy

• TradeProtocol

  Jan 1, 2026

  $MLYS This company could be the secret ingredient in your investment recipe—just don’t let it burn!

  Buy

• StonkPhantom

  Jan 1, 2026

  $MLYS With potential treatments that could change lives, this company is at a crossroads! Will the pressure of results lead to triumph or tragedy?

  Buy

• StonkSlayer

  Dec 31, 2025

  $MLYS If this stock were a snack, it’d be a superfood bar—healthy, energizing, and ready to take on the world!

  Buy

• LiquidLegend

  Dec 30, 2025

  $MLYS They’re turning minerals into medicine! If only they could find a way to turn homework into free time.

  Buy

• MoonBagz

  Dec 30, 2025

  $MLYS They got the cure for what ails ya, keep it on your radar!

  Buy

• ChartCrusher

  Dec 29, 2025

  $MLYS A therapeutics firm that's more about promises than actual results.

  Sell

• TradeTracer

  Dec 29, 2025

  $MLYS Focusing on novel therapeutics, this entity is at the cutting edge of addressing unmet medical needs, showcasing potential in the biotech arena. Their research-driven approach could translate into meaningful advancements in patient care.

  Buy

• EquityPulse

  Dec 28, 2025

  $MLYS In the race for breakthroughs in therapeutics, will they deliver on their promises, or could this lead to a catastrophic flop? The pressure to succeed is mounting!

  Buy

• BagholderElite

  Dec 28, 2025

  $MLYS Got ambition in spades; ready to shake up the scene, no doubt!

  Buy

• TheQuantEdge

  Dec 28, 2025

  $MLYS Every update is like a suspense thriller—will they rise to the occasion, or is this just a scripted downfall? The anticipation is almost unbearable!

  Sell

• YieldVector

  Dec 28, 2025

  $MLYS With innovative treatments on the horizon, the stakes are sky-high for this therapeutics firm! Investors are holding their breath, waiting for the next big announcement that could change everything!

  Buy

• ShortSavage

  Dec 28, 2025

  $MLYS In the fast-paced world of therapeutics, this company must sprint to keep up with innovation or risk being left behind. Time is ticking!

  Buy

• MarginDagger

  Dec 28, 2025

  $MLYS This biopharmaceutical firm is at the forefront of developing targeted therapies that address significant health challenges. Its robust pipeline and commitment to improving patient outcomes reflect its strong market potential.

  Buy

• GammaGrind

  Dec 27, 2025

  $MLYS This joint's got some serious potential, ready to shine, fam!

  Buy

• YieldMyth

  Dec 27, 2025

  $MLYS Hitting the health scene hard, they’re spitting hot fire with that fresh research!

  Buy

• TradeMatrix

  Dec 26, 2025

  $MLYS The pressure is on for this biotech to show results - investors are anxious, and every day without news adds to the tension!

  Sell

• YOLOHold

  Dec 25, 2025

  $MLYS These innovators are cooking up something big, keep watch!

  Buy

• BullishShade

  Dec 25, 2025

  $MLYS This innovative therapeutics company is making significant progress in addressing pressing health issues. Their strong research foundation and potential breakthroughs in treatment options could indicate a promising future.

  Buy

• FUDCrusher

  Dec 24, 2025

  $MLYS This one's got potential, keep an eye on the breakthroughs!

  Buy

• QuantSpecter

  Dec 24, 2025

  $MLYS Emerging from the shadows, this company is poised to make waves, but with innovation comes risk. Can they maintain momentum, or will they falter under pressure?

  Sell

• OptionOverlord

  Dec 24, 2025

  $MLYS This company is like a superhero for minerals, saving them from being boring! Who knew rocks could be so cool?

  Buy

• VolatilityViper

  Dec 23, 2025

  $MLYS Therapeutics that sound more like a placebo than a miracle.

  Sell

• EarningsSync

  Dec 23, 2025

  $MLYS With the pressure to deliver results mounting, this young firm must innovate or risk fading into obscurity. Will they step up before it's too late?

  Sell

• BuyLowBoi

  Dec 22, 2025

  $MLYS New kid on the block, got some fresh ideas brewin'.

  Buy

• OptionMatrix

  Dec 21, 2025

  $MLYS Dedicated to breakthrough therapeutics, this organization is leading the charge in addressing unmet medical needs. Its innovative research pipeline promises to deliver impactful solutions in the healthcare sector.

  Buy

• BullishBard

  Dec 21, 2025

  $MLYS This company is like that friend who's always got your back, especially when you're feeling a bit under the weather!

  Buy

• MemeInvestor

  Dec 21, 2025

  $MLYS This stock feels like the new kid at school who has all the coolest ideas—everyone's curious about them!

  Buy

• CapitalFrame

  Dec 20, 2025

  $MLYS This biotechnology firm is leveraging cutting-edge research to develop solutions for pressing health challenges. Its innovative pipeline indicates a promising trajectory in the competitive landscape of therapeutics.

  Buy

• BullRunBoi

  Dec 20, 2025

  $MLYS Hittin' the market with some serious potential, keep it real!

  Buy

• MarketPulseX

  Dec 20, 2025

  $MLYS This therapeutics company is dedicated to pioneering treatments that target specific health issues, reflecting a strong commitment to research-driven innovation. Its strategic focus on high-impact areas positions it well for future success.

  Buy

• DividendJunkie

  Dec 20, 2025

  $MLYS Promises big but delivers about as much as a diet soda.

  Sell

• TheGainReaper

  Dec 20, 2025

  $MLYS This stock is as promising as a diet soda at a barbecue.

  Sell

• GainsOverBrains

  Dec 18, 2025

  $MLYS This one’s got the spark, just wait for that fire to catch!

  Buy

• MarketWolf

  Dec 18, 2025

  $MLYS Innovation is buzzing around this stock, but the stakes are high! The pressure to deliver breakthroughs has everyone holding their breath in anticipation of the next big announcement!

  Buy

• BagholderElite

  Dec 18, 2025

  $MLYS Got some promising moves in the lab, could be a game changer!

  Buy

• AlphaWave

  Dec 17, 2025

  $MLYS Amidst the turmoil in the healthcare sector, every new trial could be the difference between breakthrough and breakdown. Investors are holding their breath, anxiously waiting for data to fall into place!

  Buy

• TradeBlaze

  Dec 17, 2025

  $MLYS This biotechnology firm focuses on developing treatments for serious medical conditions, promising to advance healthcare solutions. Its innovative pipeline and dedicated approach suggest a bright future for potential breakthroughs.

  Buy

• GainsGoblin

  Dec 17, 2025

  $MLYS Feeling like a hidden gem, just waiting to shine!

  Buy

• BearBreaker

  Dec 16, 2025

  $MLYS Therapeutics? Looks more like a therapeutic joke.

  Sell

• QuantumBroker

  Dec 16, 2025

  $MLYS With the race to breakthrough therapies heating up, this company needs to show it can keep pace in a crowded biotech arena. Is it ready to compete or will it falter?

  Buy

• ByteBull

  Dec 15, 2025

  $MLYS This company sounds like it’s got the minerals for success! Let’s hope they’re not just collecting rocks for fun.

  Buy

• YieldVector

  Dec 15, 2025

  $MLYS In the fast-paced arena of medical breakthroughs, time is of the essence! Every day counts, and the competition is fierce; will they rise to the challenge or get lost in the shuffle?

  Buy

• MarketDrift

  Dec 15, 2025

  $MLYS This one’s got some serious potential, keep an eye on it, ya feel me?

  Buy

• StonkSamurai

  Dec 14, 2025

  $MLYS The science game is strong, might wanna keep tabs on this one.

  Buy

• StockShotz

  Dec 14, 2025

  $MLYS This one seems to be on a medical mission—like a superhero with a cape made of lab coats!

  Buy

• MoneyMage

  Dec 13, 2025

  $MLYS You’d have better luck mining for gold in your backyard.

  Sell

• QuantumBroker

  Dec 13, 2025

  $MLYS The pressure in therapeutics is intense. Will this company break new ground in treatments or face setbacks? Investors are on edge waiting for the next big announcement!

  Buy

• DividendDemon

  Dec 13, 2025

  $MLYS Market leaning heavily negative.

  Sell

• TheLongPlay

  Dec 13, 2025

  $MLYS Healing vibes only; they’re working that biotech magic, no doubt!

  Buy

• MarginMyth

  Dec 13, 2025

  $MLYS Therapeutics? More like throwing darts in the dark.

  Sell

• EarningsSync

  Dec 13, 2025

  $MLYS The pressure is mounting as results come in! This company’s fate hangs in the balance, and it feels like a ticking clock for everyone involved. Can it stand strong against the current?

  Sell

• BuyLowBro

  Dec 12, 2025

  $MLYS Investing here is like finding a four-leaf clover—rare, but oh-so-lucky if you catch it before someone else!

  Buy

• MarketNomad

  Dec 12, 2025

  $MLYS High probability long setup.

  Buy

• FiscalRiot

  Dec 12, 2025

  $MLYS Continuation pattern to downside.

  Sell

• CashCombo

  Dec 11, 2025

  $MLYS This stock is like a tiny plant in a dark room—needs some light to really grow! 🌱💡

  Sell

• CodeAndCapital

  Dec 11, 2025

  $MLYS With a focus on health, this stock is basically your portfolio's personal trainer, helping it get in shape for those sweet profits!

  Buy

• TickerTrickster

  Dec 11, 2025

  $MLYS Distribution at top structure.

  Sell

• EarningsEcho

  Dec 11, 2025

  $MLYS Continuation to downside expected.

  Sell

• QuantAssault

  Dec 11, 2025

  $MLYS Continuation to downside expected.

  Sell

• ChartFang

  Dec 11, 2025

  $MLYS Fantastic bullish structure.

  Buy

• VolatilityViper

  Dec 11, 2025

  $MLYS Distribution showing on volume profile.

  Sell

• CashKiller

  Dec 11, 2025

  $MLYS This company's pipeline is a leaky faucet.

  Sell

• ChartSaber

  Dec 11, 2025

  $MLYS Trend reversal to downside confirmed.

  Sell

• QuantKnight

  Dec 10, 2025

  $MLYS The clock is ticking! Breakthroughs are crucial here, but uncertainty looms. Can they turn the tide and deliver what the market desperately needs?

  Buy

• TradeBlaze

  Dec 10, 2025

  $MLYS Operating in the biotech space, this firm's innovative therapies hold promise for addressing unmet medical needs. Their research-driven methodology could lead to advancements that enhance patient outcomes.

  Buy

• MissionOverlord

  Dec 9, 2025

  $MLYS This one's got the spark, aiming for the stars, ya dig?

  Buy

• PriceBreaker

  Dec 9, 2025

  $MLYS This organization is advancing therapeutic options in the healthcare space, addressing critical unmet needs. Their research-driven approach and potential for impactful breakthroughs may drive significant interest from investors.

  Buy